Get started
Author

Wolf-Dieter Janthur

Observed names: Janthur Wold-Dieter, W. Janthur, W.-D. Janthur, W.D. Janthur, Wold-Dieter Janthur, Wolf Dieter Janthur
Institution: Kantonsspital Aarau
ORCID: 0009-0005-4139-2260
Observed ORCID: 0009-0005-4139-2260
OpenAlex ID: A5110599179
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial
2021 · Sacha I. Rothschild, Alfred Zippelius, et al. · Journal of Clinical Oncology · 356
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
2020 · S. Popat, A. Curioni-Fontecedro, et al. · Annals of Oncology · 281
PDF
A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
2019 · S. Popat, A. Curioni-Fontecedro, et al. · Annals of Oncology · 56
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
2019 · S. Schmid, D. Klingbiel, et al. · Lung Cancer · 56
Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
2012 · Wolf-Dieter Janthur, Nathan Cantoni, et al. · International Journal of Molecular Sciences · 53
PDF
SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.
2020 · Sacha Rothschild, Alfred Zippelius, et al. · Journal of Clinical Oncology · 37
Comparing Two Imaging Methods for Follow-Up of Lung Cancer Treatment: A Randomized Pilot Study
2018 · Franco Gambazzi, Lukas D. Frey, et al. · The Annals of Thoracic Surgery · 27
PDF
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
2023 · A. Schuler, J. Huser, et al. · Lung Cancer · 22
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy
2025 · Dominic Schmid, Bettina Sobottka, et al. · Nature Communications · 18
PDF
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2
2020 · Michael Mark, Patrizia Froesch, et al. · Cancer Immunology Immunotherapy · 18
Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment
2024 · Sabine Schmid, Lisa Holer, et al. · JTO Clinical and Research Reports · 14
PDF
SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)—A multicenter phase II trial.
2023 · Laetitia A Mauti, Tobias Finazzi, et al. · Journal of Clinical Oncology · 14
PDF
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort
2020 · Sabine Schmid, Laetitia A. Mauti, et al. · Cancer Immunology Immunotherapy · 10
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial
2022 · Giuseppe Luigi Banna, Alfredo Addeo, et al. · Lung Cancer · 5
Image analysis in posttreatment non-small cell lung cancer surveillance: specialists’ interpretations reviewed by the thoracic multidisciplinary tumor board
2019 · Franco Gambazzi, Lukas D. Frey, et al. · Multidisciplinary Respiratory Medicine · 5
PDF
First-line immunotherapy ± chemotherapy with or without upfront stereotactic radiotherapy (SRT) in patients with Non-Small cell lung cancer (NSCLC) with asymptomatic brain metastases
2025 · Lorenz Frehner, Sämi Schär, et al. · Lung Cancer · 4
Decision-Making in Intrathecal Therapy for Leptomeningeal Disease
2026 · Susanne Weindler, Thomas Hundsberger, et al. · Oncology · 1
Abstract 7147: Ultra-high throughput single-nuclei RNAs sequencing of malignant pleural mesothelioma samples in the BEAT-MESO clinical trial
2025 · Daria Buszta, Maxim Norkin, et al. · Cancer Research · 1
Extracellular vesicles as prognostic biomarkers: results of a neoadjuvant chemoimmunotherapy clinical trial in stage IIIA (N2) non-small-cell lung cancer (SAKK 16/14)
2026 · Yannik da Silva, Dapi Menglin Chiang, et al. · Frontiers in Immunology
PDF
Abstract 2711: Large-scale integration of single-nuclei and spatial transcriptomics from the ETOP BEAT-meso trial reveals clinically relevant heterogeneity in malignant pleural mesothelioma.
2026 · Daria Buszta, Jonathan Bac, et al. · Cancer Research
EP.06.83 Prognostic Impact of PD-L1 Expression in a Swiss Cohort ofEGFR-Mutant Non-Small Cell Lung Cancer Patients Treated With First-Line Osimertinib
2025 · A. Schuler, S. Schär, et al. · Journal of Thoracic Oncology
Review of: "TROPION-Lung01 Results Indicate PFS Benefit With Datopotamab Deruxtecan Over Docetaxel in Previously Treated Nonsquamous NSCLC: A Critique and a Question"
2024 · Wolf-Dieter Janthur · Qeios
PDF
484: SAKK 16/18: QA and interim safety of immune-modulatory RT in resectable stage III(N2) NSCLC
2024 · Tobias Finazzi, Lisa Holer, et al. · Radiotherapy and Oncology
Image analysis in posttreatment non-small cell lung cancer surveillance: specialists’ interpretations reviewed by the thoracic multidisciplinary tumor board
2019 · Franco Gambazzi, Lukas D. Frey, et al. · Multidisciplinary Respiratory Medicine
PDF
P2.12-21 Outcomes with Immune Checkpoint Inhibitors (ICI) for Relapsed Small Cell Lung Cancer (SCLC) in a Swiss Cohort
2019 · L. Mauti, S. Schmid, et al. · Journal of Thoracic Oncology
PDF
Works count: 27
Citation count: 978
H-index: 12
I10-index: 13
Year
Topic
Type